SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or
"the Company"), a developer, manufacturer and marketer of implantable
visual prosthetics intended to create an artificial form of useful
vision for blind individuals, today announced that Palmetto GBA
(Jurisdiction JJ) is the latest Medicare Administrative Contractor (MAC)
to provide coverage for the Argus® II Retinal Prosthesis
System (Argus II) and the related surgical procedure. As a result of
this decision, coverage for the Argus II will now include Alabama,
Georgia and Tennessee. This brings the total coverage of the Argus II to
31 states, two territories and the District of Columbia.

“We are pleased that blind individuals with Retinitis Pigmentosa covered
by Medicare now have greater access to the Argus II with five of seven
MACs nationwide covering Argus II. We continue to work with the few
remaining MACs and payers towards the goal of achieving full coverage in
the U.S. The significant momentum in this effort reflects recognition of
our technology as the standard of care for these blind individuals,”
said Will McGuire, President and CEO of Second Sight.

Effective February 26, 2018, Palmetto GBA (Jurisdiction JJ), published a
local coverage article on the Argus II placement procedure (0100T). This
decision authorizes coverage of Argus II under the Local Coverage
Article A53044, when medically necessary, to Medicare beneficiaries in
Alabama, Georgia and Tennessee.

About Second Sight

Second Sight's mission is to develop, manufacture and market innovative
implantable visual prosthetics to enable blind individuals to achieve
greater independence. Second Sight has developed, and now manufactures
and markets, the Argus® II Retinal Prosthesis System.
Development of new hardware and software intended to improve the quality
of the vision produced by the Argus system is ongoing. Second Sight is
also developing the Orion™ Visual Cortical Prosthesis to restore some
vision to individuals who are blind due to many causes other than
preventable or treatable conditions. Second Sight’s U.S. Headquarters
are in Sylmar, California, and European Headquarters are in Lausanne,
Switzerland. For more information, please visit www.secondsight.com.

About the Argus II Retinal Prosthesis System

Second Sight's Argus II System provides electrical stimulation that
bypasses the defunct retinal cells and stimulates remaining viable cells
inducing visual perception in individuals with severe to profound
retinitis pigmentosa (RP). The Argus II works by converting images
captured by a miniature video camera mounted on the patient's glasses
into a series of small electrical pulses, which are transmitted
wirelessly to an array of electrodes implanted on the surface of the
retina. These pulses stimulate the retina's remaining cells, intending
to result in the perception of patterns of light in the brain. The
patient must learn to interpret these visual patterns, having the
potential to regain some visual function. The Argus II was the first
artificial retina to receive widespread commercial approval, and is
offered at approved centers in Canada, France, Germany, Italy, Russia,
Saudi Arabia, Singapore, South Korea, Spain, Taiwan, Turkey, the United
Kingdom, and the United States. Further information on the long-term
benefits and risks can be found in the peer reviewed paper at: http://www.sciencedirect.com/science/article/pii/S0161642016305796

Safe HarborThis press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange and
Exchange Act of 1934, as amended, which are intended to be covered by
the "safe harbor" created by those sections. All statements in this
release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as
"estimates," "anticipates," "projects," "plans," or "planned," "seeks,"
"may," "will," "expects," "intends," "believes," "should," and similar
expressions, or the negative versions thereof, and which also may be
identified by their context. All statements that address operating
performance or events or developments that Second Sight expects or
anticipates will occur in the future, such as stated objectives or
goals, or that are not otherwise historical facts, are forward-looking
statements. While management has based any forward-looking statements
included in this release on its current expectations, the information on
which such expectations were based may change. Forward-looking
statements involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of Operations
sections of our Annual Report, on Form 10-K, as filed on March 16, 2017,
and our other reports filed from time to time with the Securities and
Exchange Commission. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We caution
readers not to place undue reliance upon any such forward-looking
statements, which speak only as of the date made. Except as otherwise
required by the federal securities laws, we disclaim any obligation or
undertaking to publicly release any updates or revisions to any
forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto, or any change in events,
conditions, or circumstances on which any such statement is based.